Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GRAL
SellSinkerGRAIL, Inc. · Healthcare · United States · $3.6B · Avg Vol: $55M/d
COMPANY DESCRIPTION
GRAIL, Inc. is a healthcare company dedicated to early cancer detection through its groundbreaking multi-cancer early detection (MCED) blood test, Galleri. Its proprietary sequencing technology, extensive clinical data, and sophisticated AI algorithms create a strong competitive moat in the rapidly emerging field of precision oncology. GRAIL aims to transform cancer care by enabling earlier intervention and improving patient outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.5M | 93.1M | 125.6M | 147.2M | 38.4% | 165.3M | 181.0M | 226.7M | 24.1% |
| EPS | -173.89 | -47.21 | -63.54 | -11.11 | — | -9.69 | -7.10 | -8.94 | — |
| Shares | 31.1M | 31.1M | 33.9M | 40.3M | +29.7% | 44.7M | — | — | — |
| Debt | 96.0M | 84.4M | 68.1M | 54.9M | -17.0% | 91.3M | — | — | — |
| Equity | 0 | 0 | 2.5B | 2.6B | 3.0% | — | — | — | — |
| Op CF | -561.3M | -595.8M | -577.2M | -299.0M | — | -294.7M | — | — | — |
| Inv CF | -22.9M | -12.9M | -551.0M | -85.0M | — | — | — | — | — |
| Fin CF | 604.8M | 463.8M | 1.2B | 423.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GRAL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GRAL | GRAIL, Inc.(you) | $3.6B | 28 | Sell |
| WGS | GeneDx Holdings Corp. | $2.6B | 24 | Sell |
| ADPT | Adaptive Biotechnologies Corporation | $4.0B | 38 | Hold |
| RDNT | RadNet, Inc. | $5.9B | 34 | Sell |
| PSNL | Personalis, Inc. | $1.8B | 24 | Sell |
| FRNM | Freenome, Inc. | $1.6B | 18 | Strong Sell |
| NEO | NeoGenomics, Inc. | $2.3B | 47 | Hold |
| OPK | OPKO Health, Inc. | $1.1B | 38 | Hold |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
| BLLN | BillionToOne, Inc. | $4.4B | 61 | Hold |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%